Equities analysts expect that Epizyme Inc (NASDAQ:EPZM) will report ($0.53) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for Epizyme’s earnings, with estimates ranging from ($0.61) to ($0.47). Epizyme reported earnings of ($0.42) per share during the same quarter last year, which indicates a negative year over year growth rate of 26.2%. The firm is scheduled to announce its next quarterly earnings report on Thursday, August 1st.
On average, analysts expect that Epizyme will report full year earnings of ($2.00) per share for the current year, with EPS estimates ranging from ($2.35) to ($1.56). For the next year, analysts expect that the company will report earnings of ($1.79) per share, with EPS estimates ranging from ($2.42) to ($0.80). Zacks’ EPS averages are an average based on a survey of sell-side analysts that follow Epizyme.
Epizyme (NASDAQ:EPZM) last released its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.07. The business had revenue of $7.89 million during the quarter, compared to analysts’ expectations of $1.13 million.
In other Epizyme news, CEO Robert B. Bazemore sold 2,074 shares of the company’s stock in a transaction dated Thursday, June 13th. The shares were sold at an average price of $12.10, for a total transaction of $25,095.40. Following the completion of the sale, the chief executive officer now directly owns 87,068 shares in the company, valued at $1,053,522.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David M. Mott sold 104,944 shares of the company’s stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $13.08, for a total transaction of $1,372,667.52. Following the sale, the director now owns 13,979 shares of the company’s stock, valued at $182,845.32. The disclosure for this sale can be found here. Insiders have sold 108,203 shares of company stock valued at $1,412,101 over the last 90 days. Corporate insiders own 16.60% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the business. Primecap Management Co. CA boosted its holdings in Epizyme by 7.3% during the first quarter. Primecap Management Co. CA now owns 10,253,801 shares of the biopharmaceutical company’s stock valued at $127,045,000 after acquiring an additional 697,274 shares during the period. Redmile Group LLC lifted its stake in shares of Epizyme by 15.9% in the first quarter. Redmile Group LLC now owns 7,694,020 shares of the biopharmaceutical company’s stock valued at $95,329,000 after buying an additional 1,056,742 shares during the period. BlackRock Inc. lifted its stake in shares of Epizyme by 19.0% in the fourth quarter. BlackRock Inc. now owns 5,193,287 shares of the biopharmaceutical company’s stock valued at $31,990,000 after buying an additional 830,815 shares during the period. FMR LLC lifted its stake in shares of Epizyme by 0.3% in the first quarter. FMR LLC now owns 3,484,137 shares of the biopharmaceutical company’s stock valued at $43,169,000 after buying an additional 11,759 shares during the period. Finally, Victory Capital Management Inc. bought a new stake in shares of Epizyme in the first quarter valued at about $20,289,000. Institutional investors own 84.14% of the company’s stock.
Shares of NASDAQ EPZM traded up $0.38 during mid-day trading on Monday, reaching $13.11. The company had a trading volume of 266,161 shares, compared to its average volume of 887,216. Epizyme has a twelve month low of $5.14 and a twelve month high of $16.59. The company has a debt-to-equity ratio of 0.03, a current ratio of 12.55 and a quick ratio of 12.55. The firm has a market capitalization of $1.16 billion, a PE ratio of -7.47 and a beta of 2.47. The stock has a 50 day simple moving average of $13.36.
Epizyme Company Profile
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Featured Story: Should I follow buy, hold and sell recommendations?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.